
## Plinio Cirillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1349898/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow Journal of Biological Chemistry, 1993, 268, 18532-18541.	1.6	471
2	Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. Journal of Biological Chemistry, 1993, 268, 18532-41.	1.6	378
3	Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nature Medicine, 1996, 2, 35-40.	15.2	171
4	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovascular Research, 2005, 68, 47-55.	1.8	126
5	Antithrombotic Effects of Recombinant Human, Active Site–Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis. Circulation Research, 1998, 82, 39-46.	2.0	82
6	Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 113-118.	3.1	79
7	Î <sup>2</sup> <sub>1</sub> -Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure. Circulation, 2013, 128, 1612-1622.	1.6	69
8	Role of β 2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries. Circulation, 2005, 111, 288-294.	1.6	68
9	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal–Regulated Kinase Activation. Circulation, 2004, 109, 2911-2916.	1.6	63
10	No-Reflow Phenomenon. Angiology, 2014, 65, 180-189.	0.8	63
11	Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2014, 114, 875-882.	0.7	60
12	Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis. Circulation, 1996, 93, 1913-1918.	1.6	59
13	Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?. Current Vascular Pharmacology, 2010, 8, 259-275.	0.8	58
14	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF-ĸB-Dependent Pathway. Journal of Vascular Research, 2011, 48, 59-66.	0.6	58
15	Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology. Current Vascular Pharmacology, 2011, 9, 188-199.	0.8	52
16	Leptin Stimulated C-Reactive Protein Production by Human Coronary Artery Endothelial Cells. Journal of Vascular Research, 2009, 46, 609-617.	0.6	51
17	Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H1507-H1516.	1.5	49
18	Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: Comparison with the results of intracoronary Doppler technique. Journal of Nuclear Cardiology, 2004, 11, 682-688.	1.4	48

#	Article	IF	CITATIONS
19	Endogenous Tissue Factor Pathway Inhibitor Modulates Thrombus Formation in an In Vivo Model of Rabbit Carotid Artery Stenosis and Endothelial Injury. Circulation, 2000, 102, 113-117.	1.6	46
20	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. International Journal of Cardiology, 2013, 168, 981-986.	0.8	46
21	Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovascular Research, 1999, 43, 210-218.	1.8	43
22	Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovascular Diagnosis and Therapy, 2018, 8, 581-593.	0.7	43
23	Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes. Circulation, 2003, 108, 2864-2869.	1.6	41
24	Pro-atherothrombotic effects of leptin in human coronary endothelial cells. Thrombosis and Haemostasis, 2010, 103, 1065-1075.	1.8	41
25	Effects of Exercise Training on High-Mobility Group Box-1 Levels After Acute Myocardial Infarction. Journal of Cardiac Failure, 2011, 17, 108-114.	0.7	41
26	A Short Burst of Oxygen Radicals at Reflow Induces Sustained Release of Oxidized Glutathione from Postischemic Hearts. Free Radical Biology and Medicine, 1998, 24, 290-297.	1.3	40
27	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. Thrombosis and Haemostasis, 2015, 114, 96-108.	1.8	40
28	Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. Journal of Thrombosis and Haemostasis, 2006, 4, 2248-2255.	1.9	39
29	Increased High Mobility Group Box-1 Protein Levels are Associated With Impaired Cardiopulmonary and Echocardiographic Findings After Acute Myocardial Infarction. Journal of Cardiac Failure, 2009, 15, 362-367.	0.7	39
30	Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology, 2018, 111, 62-70.	1.0	38
31	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in in injured rabbit carotid arteries. Journal of the American College of Cardiology, 2001, 38, 569-576.	1.2	37
32	Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 119, 308-316.	0.7	37
33	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	0.8	35
34	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	0.8	35
35	Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. Journal of Thrombosis and Haemostasis, 2008, 6, 726-736.	1.9	34
36	In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. Atherosclerosis, 2008, 201, 440-446.	0.4	33

#	Article	IF	CITATIONS
37	Mid-term outcomes after percutaneous interventions in coronary bifurcations. International Journal of Cardiology, 2019, 283, 78-83.	0.8	33
38	Nicotine induces tissue factor expression in cultured endothelial and smooth muscle cells. Journal of Thrombosis and Haemostasis, 2006, 4, 453-458.	1.9	31
39	Multicentre experience with MGuardâ,,¢ net protective stent in STâ€elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion. Catheterization and Cardiovascular Interventions, 2010, 75, 715-721.	0.7	31
40	Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. Current Cardiology Reviews, 2017, 13, 110-117.	0.6	31
41	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. Journal of Cardiovascular Pharmacology, 2020, 76, 173-180.	0.8	31
42	Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis, 2010, 208, 280-284.	0.4	30
43	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2017, 4, 1.	1.1	28
44	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. Current Vascular Pharmacology, 2017, 15, 404-415.	0.8	28
45	HMG-CoA Reductase Inhibitors Reduce Nicotine-Induced Expression of Cellular Adhesion Molecules in Cultured Human Coronary Endothelial Cells. Journal of Vascular Research, 2007, 44, 460-470.	0.6	25
46	Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo : A possible contribution of immunity to thrombosis?. International Journal of Cardiology, 2016, 218, 188-195.	0.8	24
47	Activated platelets stimulate tissue factor expression in smooth muscle cells. Thrombosis Research, 2003, 112, 51-57.	0.8	23
48	Adipokines, Vascular Wall, and Cardiovascular Disease. Angiology, 2015, 66, 8-24.	0.8	23
49	Nobiletin inhibits oxidized-LDL mediated expression of Tissue Factor in human endothelial cells through inhibition of NF-κB. Biochemical Pharmacology, 2017, 128, 26-33.	2.0	23
50	Rheolytic Thrombectomy during Percutaneous Coronary Intervention Improves Long-Term Outcome in High-Risk Patients with Acute Myocardial Infarction. Journal of Interventional Cardiology, 2007, 20, 292-298.	0.5	22
51	From Femoral to Radial Approach in Coronary Intervention. Angiology, 2017, 68, 281-287.	0.8	21
52	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. Angiology, 2019, 70, 257-263.	0.8	21
53	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	1.0	21
54	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	1.1	21

#	Article	IF	CITATIONS
55	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	0.7	20
56	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis, 2020, 50, 468-472.	1.0	20
57	Aurintricarboxylic Acid Reduces Platelet Deposition in Stenosed and Endothelially Injured Rabbit Carotid Arteries more Effectively than other Antiplatelet Interventions. Thrombosis and Haemostasis, 1995, 74, 974-979.	1.8	20
58	The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells. Thrombosis Research, 2012, 130, 403-408.	0.8	19
59	Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor. Journal of Thrombosis and Thrombolysis, 2015, 40, 186-192.	1.0	19
60	MGUard versus bAreâ€metal stents plus manual thRombectomy in STâ€elevation myocarDial infarction pAtieNts—(GUARDIAN) trial: Study design and rationale. Catheterization and Cardiovascular Interventions, 2012, 79, 1118-1126.	0.7	18
61	The adipokine apelin-13 induces expression of prothrombotic tissue factor. Thrombosis and Haemostasis, 2015, 113, 363-372.	1.8	18
62	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. International Journal of Cardiology, 2018, 273, 8-14.	0.8	18
63	A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. International Journal of Cardiology, 2011, 146, 399-403.	0.8	17
64	Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF-κB pathway European Journal of Pharmacology, 2020, 885, 173422.	1.7	17
65	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS ONE, 2019, 14, e0219676.	1.1	16
66	Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. Cardiovascular Research, 2020, 116, 1125-1135.	1.8	15
67	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. Journal of Cardiovascular Development and Disease, 2022, 9, 27.	0.8	14
68	Percutaneous coronary intervention in a patient with acute nonâ€ <b>5</b> Tâ€elevation myocardial infarction and haemophilia A: a â€~ <i>genous</i> ' experience. Haemophilia, 2011, 17, e245-6.	1.0	13
69	Local cytokine production in patients with Acute Coronary Syndromes: A look into the eye of the perfect (cytokine) storm. International Journal of Cardiology, 2014, 176, 227-229.	0.8	13
70	Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt–NF-κB axis. Journal of Thrombosis and Thrombolysis, 2016, 42, 225-232.	1.0	13
71	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. American Journal of Cardiology, 2018, 122, 6-11.	0.7	13
72	Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach. Current Vascular Pharmacology, 2020, 18, 262-272.	0.8	13

#	Article	IF	CITATIONS
73	Fructose induces prothrombotic phenotype in human endothelial cells. Journal of Thrombosis and Thrombolysis, 2015, 40, 444-451.	1.0	12
74	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	0.7	12
75	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. Thrombosis Research, 1999, 96, 329-333.	0.8	11
76	Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. Journal of Thrombosis and Haemostasis, 2003, 1, 992-998.	1.9	11
77	Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?. International Journal of Cardiology, 2011, 153, 215-216.	0.8	11
78	Treatment of Residual Type A Aortic Dissection With Implantation of the Djumbodis System: Is Purely Endovascular Treatment Becoming a Reality?. Journal of Endovascular Therapy, 2011, 18, 368-373.	0.8	11
79	Reperfusion Correlates and Clinical Outcomes of Right Ventricular Dysfunction in Patients With Inferior ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 243-249.	0.7	11
80	Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. Blood Coagulation and Fibrinolysis, 2000, 11, S149-S158.	0.5	10
81	Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome. Angiology, 2014, 65, 130-136.	0.8	10
82	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. Journal of Cardiovascular Medicine, 2020, 21, 660-666.	0.6	10
83	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. Vascular Pharmacology, 2021, 137, 106822.	1.0	10
84	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. International Journal of Cardiology, 2021, 327, 176-182.	0.8	10
85	Effects of exercise-based cardiac rehabilitation on high mobility group box-1 levels after acute myocardial infarction: rationale and design. Journal of Cardiovascular Medicine, 2009, 10, 659-663.	0.6	9
86	Successful use of the Cardiva Boomerangâ,,¢ vascular closure device to close a brachial artery puncture site after emergency PTCA. Heart and Vessels, 2010, 25, 565-568.	0.5	9
87	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Internal and Emergency Medicine, 2021, 16, 1583-1591.	1.0	9
88	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1684-1689.	1.1	8
89	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. Angiology, 2018, 69, 103-112.	0.8	8
90	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. Current Vascular Pharmacology, 2020, 18, 294-301.	0.8	8

#	Article	IF	CITATIONS
91	Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?. Current Cardiology Reviews, 2010, 6, 325-332.	0.6	8
92	Cardiovascular Disease and High-Mobility Group Box 1—Is a New Inflammatory Killer in Town?. Angiology, 2013, 64, 343-355.	0.8	7
93	Quantitative detection of inducible ischemia during dobutamine stress by speckle tracking echocardiography: A dream comes true. International Journal of Cardiology, 2016, 220, 357-359.	0.8	7
94	Accuracy of global and regional longitudinal strain at peak of dobutamine stress echocardiography to detect significant coronary artery disease. International Journal of Cardiovascular Imaging, 2021, 37, 1321-1331.	0.7	7
95	Abciximab in elderly with Acute Coronary Syndrome invasively treated: Effect on outcome. International Journal of Cardiology, 2008, 130, 380-385.	0.8	6
96	Different vascular response to concurrent implantation of sirolimus- and zotarolimus-eluting stents in the same vessel. Heart and Vessels, 2009, 24, 313-316.	0.5	6
97	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8Âyears follow up study. Cardiovascular Diabetology, 2016, 15, 147.	2.7	6
98	Comparison of the Effect of Dual-Axis Rotational Coronary Angiography Versus Conventional Coronary Angiography on Frequency of Acute Kidney Injury, X-Ray Exposure Time, and Quantity of Contrast Medium Injected. American Journal of Cardiology, 2018, 121, 1046-1050.	0.7	6
99	Human heart shifts from IGF-1 production to utilization with chronic heart failure. Endocrine, 2019, 65, 714-716.	1.1	6
100	Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches. Current Vascular Pharmacology, 2017, 15, 197-206.	0.8	6
101	Multiple composite grafts (k, π or double-Y) in coronary artery surgery: a choice or a necessity?. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 60-66.	0.5	5
102	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Postâ€MI Study. Clinical Cardiology, 2019, 42, 1113-1120.	0.7	5
103	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. Journal of Thrombosis and Thrombolysis, 2022, 53, 739-749.	1.0	5
104	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clinical Cardiology, 0, , .	0.7	5
105	Latent left ventricular outflow tract obstruction induced by abnormal hypertrophic papillary muscle caused myocardial ischemia. International Journal of Cardiology, 2009, 132, 270-272.	0.8	4
106	Relationship between Pregnancy-associated Plasma Protein-A and tissue factor levels in the coronary circulation of patients with acute coronary syndrome. International Journal of Cardiology, 2018, 258, 14-16.	0.8	4
107	Anorexia nervosa–related cardiopathy in children with physical instability: prevalence, echocardiographic characteristics and reversibility at mid-term follow-up. European Journal of Pediatrics, 2021, 180, 3379-3389.	1.3	4
108	Prognostic value of 12-leads admission electrocardiogram in low-risk patients hospitalized for COVID-19. Minerva Medica, 2022, 113, .	0.3	4

#	Article	IF	CITATIONS
109	Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond. Expert Review of Cardiovascular Therapy, 2022, 20, 351-362.	0.6	4
110	True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices. Cardiovascular Revascularization Medicine, 2019, 20, 254-260.	0.3	3
111	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	0.8	3
112	Predictors of adherence to composite therapy after acute coronary syndromes. Journal of Cardiovascular Medicine, 2021, 22, 645-651.	0.6	3
113	Clinical use of cangrelor: a real world multicenter experience from South Italy Insights from the M.O.Ca. registry. Panminerva Medica, 2021, , .	0.2	3
114	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovascular Drugs and Therapy, 2023, 37, 1031-1038.	1.3	3
115	Insights into pathophysiology of smoke-related cardiovascular disease. Monaldi Archives for Chest Disease, 2008, 70, 59-67.	0.3	2
116	The pitfalls of managing thrombosis of an Absorbâ,,¢-treated bifurcation. International Journal of Cardiology, 2014, 174, e93-e95.	0.8	2
117	Diastolic dysfunction reduces stroke volume during daily's life activities in patients with severe aortic stenosis. International Journal of Cardiology, 2015, 195, 64-65.	0.8	2
118	Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry. Cardiovascular Revascularization Medicine, 2015, 16, 401-405.	0.3	2
119	Impact of drug-eluting stents on left ventricular wall motion after successful reperfusion of first anterior ST elevation myocardial infarction. Minerva Cardiology and Angiology, 2021, 69, 144-153.	0.4	2
120	Acquired left coronary artery fistula draining to the cardiac vein system after acute myocardial infarction revealed by CT scan. Clinical Imaging, 2011, 35, 395-397.	0.8	1
121	Abluminal-Coated Drug-Eluting Bifurcation-Dedicated Stent for the Treatment of Tibioperoneal Bifurcation. Vascular and Endovascular Surgery, 2017, 51, 327-330.	0.3	1
122	Antiplatelet Therapy for Non–ST-Segment Elevation Myocardial Infarction in Complex "Real―Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group― Angiology, 2017, 68, 598-607.	0.8	1
123	Lights and shadows of long-term dual antiplatelet therapy in "real life―clinical scenarios. Journal of Thrombosis and Thrombolysis, 2018, 46, 559-569.	1.0	1
124	Effects of Hypobaric Hypoxia on Endothelial Function and Adiponectin Levels in Airforce Aviators. High Altitude Medicine and Biology, 2019, 20, 165-170.	0.5	1
125	Selfâ€expandable sirolimusâ€eluting stents compared to secondâ€generation drugâ€eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILSâ€2 registries. Catheterization and Cardiovascular Interventions, 2019, 93, 208-215.	0.7	1
126	Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome. Prevention of venous thromboembolism in patients with COVID-19. International Professional Journal Medicine, 2020, 3-4, 2-7.	0.0	1

#	Article	IF	CITATIONS
127	Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thrombosis and Haemostasis, 1995, 74, 974-9.	1.8	1
128	Endovascular treatment of residual type A aortic dissection preserving patency of supra-aortic vessels by implantation of the Djumbodis® system. No more surgery for the aortic arch?. Journal of Invasive Cardiology, 2011, 23, E251-3.	0.4	1
129	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry. Panminerva Medica, 2022, , .	0.2	1
130	Adipose tissue in the pathophysiology of cardiovascular disease: Who is guilty?. World Journal of Hypertension, 2012, 2, 13.	0.8	0
131	P5581Self-expandable sirolimus-eluting stents for the treatment of the unprotected left main: propensity score-matched comparison with second generation drug-eluting stents. European Heart Journal, 2018, 39, .	1.0	0
132	P3171Impact of untreated coronary artery disease after primary percutaneous coronary intervention on two years clinical outcome: the residual added index. European Heart Journal, 2018, 39, .	1.0	0
133	4058Effects of selective and nonselective beta-blockers on platelet aggregation in patients with acute coronary syndrome: the PLATE-BLOCK study. European Heart Journal, 2018, 39, .	1.0	0
134	P6358Comparison of residual added index with residual sYNTAX score in the risk stratification of patients with incomplete coronary percutaneous revascularization after ST-elevation myocardial infarction. European Heart Journal, 2018, 39, .	1.0	0
135	P753 Impact of transcatheter aortic valve implantation on concomitant mitral regurgitation in patients with severe aortic stenosis. European Heart Journal Cardiovascular Imaging, 2020, 21, .	0.5	0
136	Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience. Coronary Artery Disease, 2020, 31, 27-34.	0.3	0
137	Multi-slice computed tomography assessment of stent position in a patient with acute coronary syndrome and anomalous origin of the coronary arteries : online article - case report. Cardiovascular Journal of Africa, 2013, 24, e1-e3.	0.2	0
138	Very late bioresorbable scaffold thrombosis and reoccurrence of dissection two years later chronic total occlusion recanalization of the left anterior descending artery. World Journal of Cardiology, 2017, 9, 710.	0.5	0
139	Bivalirudin Inhibits Thrombin-Mediated Tissue Factor Expression in Human Endothelial Cells. Journal of Advanced Therapies and Medical Innovation Sciences, 0, 2, .	0.0	0
140	652 Myocardial work in patients undergoing transcatheter aortic valve implantation: clinical value and implications for outcome. European Heart Journal Supplements, 2021, 23, .	0.0	0
141	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. European Heart Journal Supplements, 2021, 23, .	0.0	0
142	COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Atherothrombosis, 2022, 12, 114-126.	0.1	0